KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Profit After Tax: 2009-2025

Historic Profit After Tax for Jazz Pharmaceuticals (JAZZ) over the last 16 years, with Sep 2025 value amounting to $251.4 million.

  • Jazz Pharmaceuticals' Profit After Tax rose 16.91% to $251.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $565.0 million, marking a year-over-year increase of 22.00%. This contributed to the annual value of $560.1 million for FY2024, which is 35.02% up from last year.
  • Jazz Pharmaceuticals' Profit After Tax amounted to $251.4 million in Q3 2025, which was up 371.68% from -$92.5 million recorded in Q2 2025.
  • Over the past 5 years, Jazz Pharmaceuticals' Profit After Tax peaked at $251.4 million during Q3 2025, and registered a low of -$363.3 million during Q2 2021.
  • Its 3-year average for Profit After Tax is $113.4 million, with a median of $125.6 million in 2023.
  • As far as peak fluctuations go, Jazz Pharmaceuticals' Profit After Tax plummeted by 580.95% in 2022, and later surged by 4,114.94% in 2023.
  • Quarterly analysis of 5 years shows Jazz Pharmaceuticals' Profit After Tax stood at -$35.4 million in 2021, then tumbled by 580.95% to -$240.7 million in 2022, then surged by 139.11% to $94.2 million in 2023, then skyrocketed by 102.98% to $191.1 million in 2024, then rose by 16.91% to $251.4 million in 2025.
  • Its last three reported values are $251.4 million in Q3 2025, -$92.5 million for Q2 2025, and $191.1 million during Q4 2024.